S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Huge Upside Call Driving Rosetta Genomics

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Jon Ogg
Rosetta Genomics, Ltd. (NASDAQ: ROSG) has had a stellar week so far, and things are looking even better for what had been a battered microRNA-based molecular diagnostic test-maker. Dow Jones reported that a research firm called Aegis Capital has initiated coverage of Rosetta Genomics with a “Buy” rating.  Here is where the real interest may get stoked: the research firm’s price target objective is set up at $16.00 per share, supposedly as one of the most overlooked names in the molecular diagnostic group.

Shares rose on Monday from about $4.00 to just over $5.00 by Tuesday and the closing bell on Wednesday was $4.73. It is also worth noting that Rosetta just raised $27.5 million in gross proceeds earlier this month when it sold 5.5 million shares at $5.00 per share to fund its operations and for other general corporate purposes.

The report today is significant even if we haven’t ever heard of Aegis Capital.  The stock was battered and is way down from highs as the 52-week range is $1.40 to $26.70.  If you use the analyst target compared to yesterday’s close of $4.73, then the firm is projecting upside of well over 200%.  No wonder this is one of the leaderboard stocks so far with a 14% gain to $5.35 in active pre-market volume.

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Continue Reading

Jon C. Ogg |

Rosetta Genomics Joins Exponential Explosion Club on Medicare Coverage

Rosetta Genomics Ltd. (NASDAQ: ROSG) is not often in the news, but it is in the news a big way…
Why Aptorum Stock Absolutely Took Off on Tuesday
Chris Lange |

Why Aptorum Stock Absolutely Took Off on Tuesday

Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel…
Jon C. Ogg |

Rosetta Genomics Share Offering: No Good Deeds Go Unpunished

Rosetta Genomics, Ltd. (NASDAQ: ROSG) was an exponential winner on Wednesday due to getting a Medicare reimbursement ruling in its…
Jon C. Ogg |

12 Stocks Expected to Rise by 50% to 100% (or More) in 2013 (AMRN, CRZO, CNDO, EMKR, ETRM, EXAS, GALE, MX, OEDV, REGI, SPWR, SGYP)

It may seem hard to believe, but some stocks are expected to rise by 50%, 100%, or even more over…
Can Co-Diagnostics Dominate Coronavirus News Against New Competition
Jon C. Ogg |

Can Co-Diagnostics Dominate Coronavirus News Against New Competition

Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of…
247sam |

Today’s Market Winners and Losers

Stocks are down Thursday following the news that initial jobless claims rose to 372,000 last week. The Dow Jones is…
Monday’s Top Analyst Upgrades and Downgrades: CarMax, Global Payments, Infosys, JD.com, Oshkosh, WiPro and More
Lee Jackson |

Monday’s Top Analyst Upgrades and Downgrades: CarMax, Global Payments, Infosys, JD.com, Oshkosh, WiPro and More

Monday’s top analyst upgrades and downgrades included Bionano Genomics, CarMax, CNH Industrial, Global Payments, Infosys, Huya, JD.com, Oshkosh, Restaurant Brands…
Health Care In The Genomic Age
Trey Thoelcke |

Health Care In The Genomic Age

by Brett Winton, Director of Research We believe investors need to understand how genomics innovation can be a catalyst for…
10 Stocks Trading Under $10 With Massive Upside Potential in 2020
Jon C. Ogg |

10 Stocks Trading Under $10 With Massive Upside Potential in 2020

With stocks at all-time highs and after the Dow rose more than 22% and the S&P 500 rose over 28%…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618